Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 190


MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs.

Wu CP, Lusvarghi S, Tseng PJ, Hsiao SH, Huang YH, Hung TH, Ambudkar SV.

Am J Cancer Res. 2020 Jan 1;10(1):164-178. eCollection 2020.


Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models.

Lusvarghi S, Robey RW, Gottesman MM, Ambudkar SV.

F1000Res. 2020 Jan 13;9. pii: F1000 Faculty Rev-17. doi: 10.12688/f1000research.21295.1. eCollection 2020. Review.


Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.

Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS.

Cancers (Basel). 2020 Jan 12;12(1). pii: E186. doi: 10.3390/cancers12010186.


The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.

Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV.

Int J Mol Sci. 2019 Dec 29;21(1). pii: E238. doi: 10.3390/ijms21010238.


ATP-dependent thermostabilization of human P-glycoprotein (ABCB1) is blocked by modulators.

Lusvarghi S, Ambudkar SV.

Biochem J. 2019 Dec 19;476(24):3737-3750. doi: 10.1042/BCJ20190736.


Nonsynonymous Mutations in Linker-2 of the Pdr5 Multidrug Transporter Identify a New RNA Stability Element.

Rahman H, Rudrow A, Carneglia J, Joly SSP, Nicotera D, Naldrett M, Choy J, Ambudkar SV, Golin J.

G3 (Bethesda). 2020 Jan 7;10(1):357-369. doi: 10.1534/g3.119.400863.


ABC Transporter-Mediated Multidrug-Resistant Cancer.

Amawi H, Sim HM, Tiwari AK, Ambudkar SV, Shukla S.

Adv Exp Med Biol. 2019;1141:549-580. doi: 10.1007/978-981-13-7647-4_12. Review.


ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942.

Sava GP, Fan H, Fisher RA, Lusvarghi S, Pancholi S, Ambudkar SV, Martin LA, Charles Coombes R, Buluwela L, Ali S.

Oncogene. 2020 Jan;39(3):651-663. doi: 10.1038/s41388-019-1008-y. Epub 2019 Sep 17.


A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.

Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD.

Mol Pharmacol. 2019 Nov;96(5):629-640. doi: 10.1124/mol.119.115964. Epub 2019 Sep 12.


Synthesis and Characterization of Bodipy-FL-Cyclosporine A as a Substrate for Multidrug Resistance-Linked P-Glycoprotein (ABCB1).

Sajid A, Raju N, Lusvarghi S, Vahedi S, Swenson RE, Ambudkar SV.

Drug Metab Dispos. 2019 Oct;47(10):1013-1023. doi: 10.1124/dmd.119.087734. Epub 2019 Aug 1.


An A666G mutation in transmembrane helix 5 of the yeast multidrug transporter Pdr5 increases drug efflux by enhancing cooperativity between transport sites.

Arya N, Rahman H, Rudrow A, Wagner M, Schmitt L, Ambudkar SV, Golin J.

Mol Microbiol. 2019 Oct;112(4):1131-1144. doi: 10.1111/mmi.14351. Epub 2019 Jul 23.


Evidence for the Interaction of A3 Adenosine Receptor Agonists at the Drug-Binding Site(s) of Human P-glycoprotein (ABCB1).

Abel B, Tosh DK, Durell SR, Murakami M, Vahedi S, Jacobson KA, Ambudkar SV.

Mol Pharmacol. 2019 Aug;96(2):180-192. doi: 10.1124/mol.118.115295. Epub 2019 May 24.


Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.

Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV.

Mol Pharm. 2019 Jul 1;16(7):3040-3052. doi: 10.1021/acs.molpharmaceut.9b00274. Epub 2019 Jun 4.


Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells.

Cui Q, Cai CY, Gao HL, Ren L, Ji N, Gupta P, Yang Y, Shukla S, Ambudkar SV, Yang DH, Chen ZS.

Front Oncol. 2019 Apr 25;9:313. doi: 10.3389/fonc.2019.00313. eCollection 2019.


Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells.

Baglo Y, Liang BJ, Robey RW, Ambudkar SV, Gottesman MM, Huang HC.

Cancer Lett. 2019 Aug 10;457:110-118. doi: 10.1016/j.canlet.2019.04.037. Epub 2019 May 6.


Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities.

Sana G, Madigan JP, Gartner JJ, Fourrez M, Lin J, Qutob N, Narayan J, Shukla S, Ambudkar SV, Xia D, Rosenberg SA, Gottesman MM, Samuels Y, Gillet JP.

J Invest Dermatol. 2019 Sep;139(9):1985-1992.e10. doi: 10.1016/j.jid.2019.01.036. Epub 2019 Mar 21.


Large-scale purification of functional human P-glycoprotein (ABCB1).

Nandigama K, Lusvarghi S, Shukla S, Ambudkar SV.

Protein Expr Purif. 2019 Jul;159:60-68. doi: 10.1016/j.pep.2019.03.002. Epub 2019 Mar 6.


The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.

Hsiao SH, Lusvarghi S, Huang YH, Ambudkar SV, Hsu SC, Wu CP.

Cancer Lett. 2019 Mar 31;445:34-44. doi: 10.1016/j.canlet.2019.01.001. Epub 2019 Jan 11.


Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.

Zhang YK, Wang YJ, Lei ZN, Zhang GN, Zhang XY, Wang DS, Al-Rihani SB, Shukla S, Ambudkar SV, Kaddoumi A, Shi Z, Chen ZS.

Cancer Lett. 2019 Feb 1;442:104-112. doi: 10.1016/j.canlet.2018.10.032. Epub 2018 Oct 28.


Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.

Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, Shukla S, Ambudkar SV, Kong D, Chen ZS.

Cancer Lett. 2019 Jan;440-441:82-93. doi: 10.1016/j.canlet.2018.10.007. Epub 2018 Oct 10.


Supplemental Content

Loading ...
Support Center